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The present study evaluated the clinical significance of hepatocyte growth factor (HGF) in patients with pulmonary 
fibrosis. Twenty-one patients with a diagnosis of pulmonary fibrosis [14 with idiopathic pulmonary fibrosis (IPF) 
and seven with pulmonary fibrosis associated with a collagen vascular disorder (PF-CVD)] and 21 normal subjects 
as control were studied. HGF levels in sera of patients with pulmonary fibrosis (0.34 % 0.02 ng ml - ‘) were elevated 
significantly as compared with normal subjects (0.21 f 0.01 ng ml- ‘) (P<O.OOOl). HGFlalbumin levels in broncho- 
alveolar lavage fluid (BALF) of patients with pulmonary fibrosis (72 Z!Z 17 ng g - ’ albumin) were also significantly 
elevated as compared with normal subjects (under the detection limit) (JQO.01). HGF levels in sera correlated 
significantly with elastase levels in sera and C-reactive protein, and correlated negatively with PaO,. HGF levels in 
sera were significantly higher in smokers with pulmonary fibrosis (0.42 f 0.03 ng ml- ‘) as compared with 
non-smokers with pulmonary fibrosis (0.29 & 0.03 ng ml - ‘) (P<O.OOS). HGF/albumin levels in BALF correlated 
significantly with elastase/albumin levels in BALF, lactate dehydrogenaselalbumin in BALF, Immunoglobulin 
A/albumin in BALF, total cell count/albumin in BALF, total number of alveolar macrophage/albumin in BALF, 
total number of neutrophillalbumin in BALF, CEAlalbumin in BALF, CA19-9/albumin in BALF, and SCC/ 
albumin in BALF. These results suggest that following lung injury, HGF may be a mediator involved in the repair 
which leads to pulmonary fibrosis. 
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Introduction 
Idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis 
associated with collagen vascular disorder (PF-CVD) are 
chronic lung diseases of unknown aetiology which are 
characterized by the accumulation of neutrophils, eosi- 
nophils and mononuclear cells (l-3). These are followed 
by the progressive deposition of collagen within the 
interstitium, and subsequent destruction of lung airspace, 
loss of functional lung units and development of pulmonary 
fibrosis (4). Recently, it was reported that hepatocyte 
growth factor (HGF) in serum is increased in patients with 
Received 14 April 1997 and accepted in revised form 4 August 
1997. 
Correspondence should be addressed to: J. Fujita, First Depart- 
ment of Internal Medicine, Kagawa Medical University, 1750-1, 
Miki-cho, Kita-gun, Kagawa, 761-07, Japan. 
0954.6111/98/020273+06 $12.00/O 
inflammatory lung disease (5). In the lung HGF is synthe- 
sized and secreted by mesenchymal cells, such as macro- 
phages, endothelial cells and fibroblasts (6). HGF controls 
proliferation and morphogenesis of epithelial cells (6). It 
has recently been revealed that the lung has en endocrine 
function and produces HGF for the regeneration of injured 
tissues or organs (7). HGF also acts as a pulmotrophic 
factor in lung regeneration after acute lung injury (7), and 
is a potential paracrine growth factor for rat alveolar type 
II cells in primary culture (6). Therefore, it has been 
hypothesized that HGF might play an important role in 
regulating the growth of lung epithelium, and in the regen- 
eration of the lung as a paracrine or endocrine factor in 
pulmonary fibrosis. However, the role of HGF in patients 
with pulmonary fibrosis still remains unclear. In order to 
evaluate correlations between HGF and other factors, the 
following parameters were measured in patients with IPF 
and patients with PF-CVD. 
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Methods 
STUDY POPULATION 
Twenty-one patients with a diagnosis of pulmonary fibrosis 
in Kagawa Medical Hospital (613 beds) and Matsuyama 
Citizen Hospital (538 beds) were studied from 1990 to 1996. 
Of the 21 patients, 14 had IPF and seven had PF-CVD 
(three had rheumatoid arthritis, three had dermatomyositis 
and one had Sjogren syndrome). Median age of the patients 
was 69 years with a range of 4486 years (13 men and eight 
women). There were 14 non-smokers four ex-smokers 
and three current smokers. The diagnoses were made by 
clinical, radiological, physiological and histological 
grounds. The criteria used included: history of exertional 
dyspnoea and cough, fine crackles on physical examination, 
compatible findings on the chest radiograph (diffuse basal 
reticulonodular shadows), physiological abnormalities 
of restrictive lung defect including decreased diffusing 
capacity, and abnormal PaO, at rest and/or with exertion. 
Histological confirmation was obtained in call cases by 
open lung biopsy. The histology of all patients 
with PF-CVD were usual interstitial pneumonia (UIP) 
pattern. In all patients, high-resolution computed radio- 
graphic scanning of the lungs (HRCT) was performed (1, 
8). All patients received no immunosuppressive treatment 
such as corticosteroid or cyclophosphamide. Twenty-one 
normal subjects (15 non-smokers and six smokers) 
were also studied (average age 55 years). All subjects had no 
history of lung disease, no clinical findings suggesting 
lung disease, and no liver and renal dysfunction. They all 
had normal chest X-rays and their pulmonary function 
test results were within a normal limit. Ten cases (seven 
smokers and three smokers) of 21 normal subjects 
could be studied for bronchoalveolar lavage (BAL). The 
protocols were approved by the institutional review 
board for human studies, and informed written consent 
was obtained. 
BLOOD SAMPLES 
Peripheral venous blood samples with and without ethy- 
lenediaminetetraacetic acid (EDTA) were obtained before 
breakfast. After centrifugation at 1000 g for 10 min at 4°C 
the serum was frozen and stored at - 70°C until used. 
Arterial blood samples were analysed for PaO, and PCO, 
using a blood gas analyser. 
BRONCHOALVEOLAR LAVAGE 
After the upper airway was anaesthetized with topical 
lignocaine, a flexible fibre-optic bronchoscope was wedged 
into the lower respiratory tract under visualization. To 
sample the lower respiratory tract, BAL was performed 
by infusing three 50 ml aliquots of sterile saline at the 
site of the anterior segment of the right lower lobe. The last 
two aliquots were saved for evaluation. The fluid 
was filtered through gauze, and cells were separated 
from alveolar lavage fluid by centrifugation (300g for 
10 min). BAL fluid (BALF) was frozen and stored at 
- 70°C until used. 
MEASUREMENT OF HGF LEVELS IN SERUM 
AND BALF 
HGF was measured by enzyme-linked immunosorbent 
assay (ELISA) with monoclonal and polyclonal antibodies 
against human HGF (Otsuka Assay Laboratories, 
Tokushima, Japan). This assay was calibrated using stan- 
dard solutions of known HGF concentrations. The lower 
detection limit of this assay was 0.02 ng ml - ‘. When HGF 
levels in BALF were under the detection limit in a patient 
group, the BALF was concentrated five times using the 
lyophilization method. Data were expressed as mean values 
from duplicate determinations. 
Peripheral blood samples were measured for white blood 
cell counts and erythrocyte sedimentation rate (ESR). The 
serum samples were analysed for HGF, elastase, C-reactive 
protein (CRP), lactase dehydrogenase (LDH) and Immu- 
noglobulin G (IgG). The BALF samples were analysed for 
HGF, elastase, LDH, carcinoembryonic antigen (CEA), 
CA19-9, squamous cell carcinoma related antigen (SCC), 
IgG, IgA, albumin and cellular profiles. These tumour 
markers were measured by radioimmunoassay. Elastase 
levels in serum and BALF were determined by using an 
ELISA kit purchased from Merck (Diagnostica Merck, 
Darmstadt, Germany). To exclude the effect of dilution, 
data in BALF were corrected by albumin (divided each 
datum by albumin). As a pulmonary function test, %VC 
and FEVl.O% were measured in all patients. 
HGF in sera and BALF were also measured in normal 
subjects, and compared with the results of patients with 
pulmonary fibrosis. In patients with pulmonary fibrosis, 
correlations between each parameters were evaluated, and 
the difference of the HGF levels in serum and BALF were 
compared between non-smokers as well as ex-smokers and 
current smokers. 
STATISTICAL METHODS 
Data are expressed as means & standard error of the mean. 
Mann-Whitney U-test was used for the comparison 
between individual groups. Correlations were evaluated by 
the Pearson’s correlation coefficient, and Fisher’s Y to z 
method was used to calculate the P values. Statistical 
significance was assumed for P<O.O5. 
Results 
Figure 1 shows the HGF levels in sera [Fig. l(a)] and in 
BALF [Fig. l(b)] of normal subjects and patients with 
pulmonary fibrosis. HGF levels in sera of patients with 
pulmonary fibrosis (0.34 & 0.02 ng ml - ‘) were elevated 
significantly compared with normal subjects (0.21 * 0.01 ng 
ml- ‘) (P<O.OOOl). HGF/albumin levels in BALF of 
HEPATOCYTE GROWTH FACTOR IN PULMONARY FIBROSIS 275 
P < 0.0001 
0.6L 
. 
Normal 
(b) 
P < 0.01 
. 
. 
Normal Pulmonary 
fibrosis 
FIG. 1. Serum HGF levels in normal subjects and patients with pulmonary fibrosis (a), and BALF HGF levels in normal 
subjects and patients with pulmonary fibrosis (b). 
patients with pulmonary fibrosis (72 f 17 ng g- ’ albumin) 
were also significantly elevated as compared with normal 
subjects (under the detection limit) (WO.01). Correlations 
between HGF levels in sera and other parameters in 
patients with pulmonary fibrosis are shown in Table 1 (a). 
HGF levels in sera correlated significantly with elastase 
levels in sera (~~0.566, P<O.Ol), CRP (r=0.586, WO.005) 
and correlated negatively with PaO, (Y= - 0.613, P<O.O05). 
Correlations between HGF/albumin levels in BALF and 
other parameters in patients with pulmonary fibrosis are 
shown in Table 1 (b). HGFlalbumin levels in BALF corre- 
lated significantly with elastase/albumin levels in BALF 
(~~0.642, P<O.O05), LDH/albumin in BALF (r=0.716, 
P<O.O05), &A/albumin in BALF (r=0.490, P<O.O5), total 
cell count/albumin in BALF (r=0.745, P<O.OOOl), total 
number of alveolar macrophage/albumin in BALF 
(r=0.745, P<O.OOOl), total number of alveolar neutrophil/ 
albumin in BALF (~~0.644, P<O.O05), CEAlalbumin in 
BALF (rz0.72, P<O.OOOl), CA19-/albumin in BALF 
(r=0.646, P<O.O05), and KC/albumin in BALF (r=0.488, 
P<O.O5). Serum HGF levels of current smokers 
(0.42 f 0.03 ng ml- ‘) were significantly higher than non- 
smokers and ex-smokers (0.29 f 0.03 ng ml - ‘) (P<O.O05). 
The ratio of HGFlalbumin in BALF divided by serum 
HGF/serum albumin concentration was 8.7 & 2.0. 
Discussion 
It has been reported that HGF is an important growth 
factor for various epithelial cells, and it has a mitogenic, 
motogenic, morphogenic and tumour suppressive function 
(9-12). In addition, it has been reported that HGF is shown 
to be a mitogen for the rat alveolar type II cells in primary 
culture (6). Previously, the present authors have shown 
that serum HGF concentration in patients with pneumonia 
was significantly higher as compared with patients 
without pneumonia, and the increase of serum HGF 
followed shortly after the onset of inflammation (13). This 
suggests that HGF has a important role in regeneration 
of the lung following acute lung injury, and HGF could 
be an indicator of lung repair after lung damage in 
patients with lung disease (13). In addition, Maeda et al. 
have also suggested that serum HGF levels increase in 
inflammatory lung diseases including interstitial pneumoni- 
tis, and HGF levels in the surviving patients decrease 
rapidly with treatment (5). In the present study, the increase 
of HGF in sera was confirmed, and the increase of HGF 
levels in BALF of patients with pulmonary fibrosis 
was demonstrated. There was no significant difference of 
HGF levels in sera or BALF between patients with IPF 
and patients with PF-CVD. Therefore, data from both 
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TABLE 1. Correlations between (a) serum HGF levels and other parameters, and (b) BALF HGF 
levels and other parameters 
Parameter R P 95% Confidence intervals 
(4 
Serum elastase 
CRP 
Serum LDH 
Serum IgG 
PaO, 
PaCO, 
WBC 
ESR 
%VC 
FEVl.O% 
BALF HGFlalbumin 
BALF LDH/albumin 
BALF-CEA/albumin 
BALF CA 19-9/albumin 
BALF SCC/albumin 
BALF elastase/albumin 
BALF IgG/albumin 
BALF IgA/albumin 
TCC/albumin 
Ma/albumin 
Nt/albumin 
Lylalbumin 
Eo/albumin 
@I 
Serum elastase 
Serum HGF 
CRP 
Serum LDH 
Serum IgG 
PaO, 
PaO, 
WBC 
ESR 
%VC 
FEVl.0 
BALF LDH/albumin 
BALF CEA/albumin 
BALF CAl9-B/albumin 
BALF SCC/albumin 
BALF elastase/albumin 
BALF IgG/albumin 
BALF IgA/albumin 
TCC/albumin 
Ma/albumin 
Nt/albumin 
Lylalbumin 
Eolalbumin 
0.566 
0.586 
0.054 
0.054 
- 0.613 
- 0.092 
0.217 
- 0.355 
0.010 
0.296 
0.091 
- 0.267 
- 0.030 
- 0.020 
- 0.232 
- 0.240 
0.130 
- 0.161 
- 0.295 
0.022 
- 0.146 
- 0.395 
0.056 
- 0.255 
0.086 
- 0.133 
- 0.129 
- 0.171 
0.131 
0.104 
- 0.050 
0.446 
- 0.175 
0.055 
0.717 
0.723 
0.647 
0.489 
0.643 
0.228 
0.490 
0.745 
0.745 
0.644 
- 0.207 
0.292 
co.01 
co.05 
N.S. 
N.S. 
co.05 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
co.005 
<0~0001 
co.005 
co.05 
co.005 
N.S. 
co.05 
<0~0001 
<0~0001 
co.005 
N.S. 
N.S. 
0.178-0.802 
0.207-0.812 
- 0.348-0440 
- 0.41330.394 
- 0.826- 0.247 - 
- 0.503-0.354 
- 0.2040.571 
- 0.697-0.118 
- 0.430-0.413 
- 0.183-0.661 
- 0.3540.503 
- 0.6740.263 
- 0.370-0.420 
- 0.412-0.378 
- 0.5740.180 
- 0.593-0192 
- 0.507-0.288 
- 0.53GO.259 
- 0.8960.187 
- 0.3940.430 
0.52770.283 
- 0.6940.021 
- 0.3640.458 
- 0.636-0.225 
- 0.38330.52 
- 0.577-0.371 
- 0.53 l-0.321 
- 0.561-- 0.281 
- 0.374-0.575 
- 0.367-0.533 
- 0.482-0.401 
- 0.064-0.771 
- 0.58330.303 
- 0.4234509 
0~301-0~904 
0.423-0.880 
0.299-0.843 
0.072-0.760 
0.266-0.849 
- 0.2260.601 
0.075-0.761 
0.44-0.896 
0.440.896 
0.268-0.85 
- 0.6040.273 
- 0.1874.659 
N.S., not significant; TCC, total cell counts; Ma, alveolar macrophages; Nt, neutrophils; Ly, 
lymphocytes; Eo, eosinophils. 
HEPATOCYTEGROWTH FACTORIN PULMONARYFIBROSIS 277 
patients with IPF and patients with PF-CVD were 
handled together. 
In addition, the correlations between HGF and other 
parameters in patients with pulmonary fibrosis were evalu- 
ated. Although Maeda et al. reported that there is no 
significant correlation between serum HGF and CRP as 
well as PaO, (5), HGF levels in sera correlated significantly 
with elastase levels in sera and CRP, and correlated 
negatively with PaO, in the present study. This controversy 
might be explained by the difference of patient selection 
(they included hypersensitivity pneumonitis and bacterial 
pneumonia) (5). 
Correlation between HGF in sera and elastase in sera 
seemed to be very interesting. As HGF is believed to play 
an important role in the process of lung regeneration, HGF 
in sera might increase in response to the excess of elastase 
which is considered to be a destructive factor. 
Tumour markers are believed to be released from lung 
epithelial cells, and secretory IgA is produced by the 
epithelial cells of the respiratory tract (14). If epithelial cells 
are damaged by destructive factor such as neutrophil 
elastase (15), it is possible to consider that LDH, CEA, 
CAl9-9, SCC and IgA are released from epithelial cells and 
represent the degree of epithelial cell damage. In addition, 
followed by the epithelial cell damage, HGF might act on 
type II cells to regenerate the epithelium. 
As the detection limit of the HGF assay was 0.02 ng 
ml ~ ‘, it is frequently difficult to detect HGF in BALF. 
Although the BALF was concentrated five times using 
the lyophilization method. almost eight patients with pul- 
monary fibrosis have undetectable levels of HGF in their 
bronchial alveolar fluid. However, if BALF was concen- 
trated more than five times, it may be possible to demon- 
strate the difference of BALF HGF levels between patients 
with pulmonary fibrosis and normals. 
The ratio of HGF/albumin in BALF divided by serum 
HGF/serum albumin concentration was more than 1.0. In 
addition, the authors also demonstrated that HGF/albumin 
in BALF correlated strongly with total number of alveolar 
macrophagelalbumin. These results suggested that most 
HGF in the alveolus might be produced locally by alveolar 
macrophages. In fact, the production of HGF by alveolar 
macrophage has been reported very recently using i/z situ 
hybridization (16). 
Interestingly, HGF levels in sera of smokers with pul- 
monary fibrosis were significantly higher when compared 
with non-smokers and ex-smokers. As smoking is one of the 
poor prognostic factors of IPF, this evidence may also 
explain why HGF responded to the lung injury caused by 
smoking. An analysis of the effects of smoking on HGF in 
a much larger number of persons will be required in the 
future. 
The authors also evaluate the clinical significance of 
HGF as a prognostic factor. However, the follow-up period 
of the study population was not enough; no results have 
been obtained at present. 
In conclusion, these data demonstrated: (i) HGF in 
serum and BALF was increased in patients with pulmonary 
fibrosis; and (ii) HGF in serum and BALF correlated with 
clinical parameters in pulmonary fibrosis. These results 
suggest that HGF may play a role in the process of lung 
injury and repair in pulmonary fibrosis. 
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